(PR-inside.com) POTSDAM, GERMANY -- (Marketwire) -- 01/20/12 -- Signature Diagnostics / SignatureDiagnostics to Present a novel Companion Diagnostic Product PredictingResponse to Cetuximab in Colorectal Cancer at the ASCO 2012Gastrointestinal Cancer Symposium in San Francisco. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.Potsdam, Germany, January 20, 2012 - Signature Diagnostics AG announcedtodaythat the company was selected to present its novel companiondiagnostics forpredicting response to cetuximab in patients with colorectal cancer (CRC)of allstages at the ASCO 2012 Gastrointestinal Cancer Symposium in SanFrancisco onJanuary 19-21, 2012. The paper, "Use of wild-type (wt) KRAS, BRAF, ..

More...